IndustryCompany release

Cartesian expects Phase 3 AURORA myasthenia gravis readout in 1Q27, with BLA planned for mid-2027

🇺🇸 Cartesian Therapeutics, Inc. (RNAC) · Thu 05 Nov 2026

The CAR-T developer says Descartes-08 data in AChR antibody-positive myasthenia gravis are due in the first quarter of 2027, ahead of a planned FDA filing, as it reports Q3 2026 results.

Cartesian Therapeutics reported its third-quarter 2026 results on 5 November, confirming that the Phase 3 AURORA trial of Descartes-08 in AChR antibody-positive myasthenia gravis (MG) should read out in the first quarter of 2027. The company plans to submit a Biologics License Application (BLA) to the US Food and Drug Administration in mid-2027.

Descartes-08 is an anti-BCMA CAR-T therapy. Cartesian also presented retreatment data in five MG patients, who showed a mean 6.6-point reduction in MG-ADL score at Month 12. The company reported no new safety signals in this group.

Further data are expected in the first half of 2027 from the TRITON study in myositis and the HELIOS study in paediatric patients.

On finances, Cartesian reported cash of $124.7 million, a figure that includes an initial $50 million tranche from K2HealthVentures. It expects this to fund operations into 2028. The net loss for the third quarter was $11.5 million.

What it means for your team

  • The AURORA readout in 1Q27 is the key gating event for the mid-2027 BLA timeline; regulatory teams tracking cell-therapy filings in neuromuscular disease should note both dates.
  • The retreatment data come from only five patients, and the company reported no new safety signals; pharmacovigilance observers will want larger datasets on repeat dosing.
  • TRITON (myositis) and HELIOS (paediatric) data in 1H27 point to possible expansion beyond adult MG, which market-access teams may want to factor into long-range planning.
  • The company's stated cash runway into 2028 covers the planned readout and filing window.

Company's press release (SEC filing): Cartesian Therapeutics, Inc. ↗

Article written by VigiEye from the official source (Cartesian Therapeutics, Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →